These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 23032365)

  • 1. Scheduling of anticancer drugs: timing may be everything.
    Van der Veldt AA; Lammertsma AA; Smit EF
    Cell Cycle; 2012 Dec; 11(23):4339-43. PubMed ID: 23032365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualized treatment planning in oncology: role of PET and radiolabelled anticancer drugs in predicting tumour resistance.
    van der Veldt AA; Luurtsema G; Lubberink M; Lammertsma AA; Hendrikse NH
    Curr Pharm Des; 2008; 14(28):2914-31. PubMed ID: 18991710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiolabelled probes targeting tumor hypoxia for personalized medicine.
    Mees G; Sathekge M; Maes A; Van de Wiele C
    Curr Pharm Des; 2014; 20(14):2308-18. PubMed ID: 24025104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Targeting Using Radiolabeled Antibodies for Image-Guided Drug Delivery.
    Rijpkema M; Boerman OC; Oyen WJ
    Curr Drug Targets; 2015; 16(6):625-33. PubMed ID: 25355181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First clinical study of a pegylated diabody
    Scott AM; Akhurst T; Lee FT; Ciprotti M; Davis ID; Weickhardt AJ; Gan HK; Hicks RJ; Lee ST; Kocovski P; Guo N; Oh M; Mileshkin L; Williams S; Murphy D; Pathmaraj K; O'Keefe GJ; Gong SJ; Pedersen JS; Scott FE; Wheatcroft MP; Hudson PJ
    Theranostics; 2020; 10(25):11404-11415. PubMed ID: 33052222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of PET/CT in the development of novel anticancer drugs.
    Boss DS; Olmos RV; Sinaasappel M; Beijnen JH; Schellens JH
    Oncologist; 2008 Jan; 13(1):25-38. PubMed ID: 18245010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiolabelled tracers and anticancer drugs for assessment of therapeutic efficacy using PET.
    Brady F; Luthra SK; Brown GD; Osman S; Aboagye E; Saleem A; Price PM
    Curr Pharm Des; 2001 Dec; 7(18):1863-92. PubMed ID: 11772355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Realizing the full potential of PET for measuring the biodistribution of novel anticancer agents.
    Jones T; Price P; Tavitian B
    J Nucl Med; 2011 Sep; 52(9):1500. PubMed ID: 21824989
    [No Abstract]   [Full Text] [Related]  

  • 9. PET screening of anticancer drugs. A faster route to drug/target evaluations in vivo.
    Fredriksson A; Stone-Elander S
    Methods Mol Med; 2003; 85():279-94. PubMed ID: 12710215
    [No Abstract]   [Full Text] [Related]  

  • 10. Positron emission tomography (PET): expanding the horizons of oncology drug development.
    Hammond LA; Denis L; Salman U; Jerabek P; Thomas CR; Kuhn JG
    Invest New Drugs; 2003 Aug; 21(3):309-40. PubMed ID: 14578681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational design of caspase-responsive smart molecular probe for positron emission tomography imaging of drug-induced apoptosis.
    Qiu L; Wang W; Li K; Peng Y; Lv G; Liu Q; Gao F; Seimbille Y; Xie M; Lin J
    Theranostics; 2019; 9(23):6962-6975. PubMed ID: 31660080
    [No Abstract]   [Full Text] [Related]  

  • 12. Radiopharmaceuticals for oncology drug development: a pharmaceutical industry perspective.
    Murphy PS; Bergström M
    Curr Pharm Des; 2009; 15(9):957-65. PubMed ID: 19275660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iodine-124: a promising positron emitter for organic PET chemistry.
    Koehler L; Gagnon K; McQuarrie S; Wuest F
    Molecules; 2010 Apr; 15(4):2686-718. PubMed ID: 20428073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of structural alterations on the radiopharmacological profile of
    Tietz O; Marshall A; Bergman C; Wuest M; Wuest F
    Nucl Med Biol; 2018; 62-63():9-17. PubMed ID: 29800798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo preclinical evaluation of the new
    Trencsényi G; Kis A; Szabó JP; Ráti Á; Csige K; Fenyvesi É; Szente L; Malanga M; Méhes G; Emri M; Kertész I; Vecsernyés M; Fenyvesi F; Hajdu I
    Int J Pharm; 2020 Feb; 576():118954. PubMed ID: 31935470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positron emission tomography for use in microdosing studies.
    Wagner CC; Müller M; Lappin G; Langer O
    Curr Opin Drug Discov Devel; 2008 Jan; 11(1):104-10. PubMed ID: 18175273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody positron emission tomography imaging in anticancer drug development.
    Lamberts LE; Williams SP; Terwisscha van Scheltinga AG; Lub-de Hooge MN; Schröder CP; Gietema JA; Brouwers AH; de Vries EG
    J Clin Oncol; 2015 May; 33(13):1491-504. PubMed ID: 25779566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The next generation of positron emission tomography radiopharmaceuticals in oncology.
    Rice SL; Roney CA; Daumar P; Lewis JS
    Semin Nucl Med; 2011 Jul; 41(4):265-82. PubMed ID: 21624561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.
    Van der Veldt AA; Lubberink M; Bahce I; Walraven M; de Boer MP; Greuter HN; Hendrikse NH; Eriksson J; Windhorst AD; Postmus PE; Verheul HM; Serné EH; Lammertsma AA; Smit EF
    Cancer Cell; 2012 Jan; 21(1):82-91. PubMed ID: 22264790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vivo Targeting and Positron Emission Tomography Imaging of Tumor with Intrinsically Radioactive Metal-Organic Frameworks Nanomaterials.
    Chen D; Yang D; Dougherty CA; Lu W; Wu H; He X; Cai T; Van Dort ME; Ross BD; Hong H
    ACS Nano; 2017 Apr; 11(4):4315-4327. PubMed ID: 28345871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.